Evrópusambandið - íslenska - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - afturköllun taugavöðvablokkunar sem valdið er af rócuronium eða vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

piramal critical care b.v. - sugammadex sodium - taugakerfi - sugammadex - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - taugakerfi - Öll önnur lækningavörur - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

hameln pharma gmbh - sugammadex sodium - stungulyf, lausn - 100 mg/ml

Evrópusambandið - íslenska - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - lyf notuð við sykursýki - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Evrópusambandið - íslenska - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - astma - lyf til veikindi öndunarvegi sjúkdómum, - budesonid / formoterol teva pharma b. er ætlað fullorðnum 18 ára og eldri. asthmabudesonide/formóteróli sjá pharma b. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists. in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

uni-pharma kleon tsetis pharmaceutical laboratories s.a. - thiamazolum inn - tafla - 5 mg

Evrópusambandið - íslenska - EMA (European Medicines Agency)

teva pharma b.v.  - budesonide, formoterol fumarate dihydrate - asthma; pulmonary disease, chronic obstructive - lyf til veikindi öndunarvegi sjúkdómum, - budesonid / formoterol teva pharma b. er ætlað fullorðnum 18 ára og eldri. asthmabudesonide/formóteróli sjá pharma b. er gefið til kynna í reglulega meðferð asma, þar að nota sambland (andað barksteri og langverkandi β2 adrenviðtaka örva) er rétt:-í sjúklingar ekki nægilega stjórnað með andað krefur og "og þarf" andað skamms vinna β2 adrenviðtaka örvum. eða-í sjúklinga þegar nægilega stjórn á báðum andað krefur og langverkandi β2 adrenviðtaka örvum. copdsymptomatic meðferð sjúklinga með llt með afl útöndunarmagni í 1 annað (fev1) .